Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

Rouf, Nusrat Zahan; Biswas, Sumit; Tarannum, Nawseen; Oishee, Labiba Mustabina; Muna, Mutia Masuka

doi:10.1080/15476286.2022.2055923

Cited by 23 publications

(23 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The enthusiasm for innovation is widely shared. The examples of rapid and remarkable innovation during the pandemic have acquired something of a legendary quality—ranging from the Mercedes FI involvement in producing a ventilation device [ 17 ] to the capacity to design a DNA or mRNA vaccine [ 18 ] within days of acquiring the genetic sequence of a new pathogen, to identify a lead candidate for clinical trials within weeks and have millions of doses manufactured within months [ 19 ].…”

Section: Discussion: Different Challenges and Opportunitiesmentioning

confidence: 99%

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

et al. 2022

View full text Add to dashboard Cite

Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists’ discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.

show abstract

Section: Discussion: Different Challenges and Opportunitiesmentioning

confidence: 99%

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Factors such as the length of the poly(A) tail and structure of the 5 0 cap can improve the stability of the mRNA by controlling the type and amount of protein binding. 35,36 In addition, codon optimization and nucleoside modification of the mRNA sequence has shown to improve the translation efficiency and reduce immunogenicity. 37 Recent efforts at designing modified therapeutic mRNA have been covered extensively in otherworks.…”

Section: Methods For Mrna Deliverymentioning

confidence: 99%

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

2023

View full text Add to dashboard Cite

show abstract

“…As with most drugs, side effects with mRNA-LNP vaccines often increase with dose. For example, for the mRNA-1273 vaccine, 100 μg of the dose showed good efficacy and minimal side effects, and 250 μg of the vaccine caused severe side effects, while the BNT162b2 vaccine at 30 μg showed better efficacy and minimal side effects ( 82 , 83 ). Anaphylactic reactions and inflammatory reactions have been observed with some COVID-19 mRNA-LNP vaccines, even at the recommended doses ( 84 – 86 ).…”

Section: Rational Design and Optimization Of Mrna Cancer Vaccinesmentioning

confidence: 99%

mRNA vaccines for cancer immunotherapy

Vishweshwaraiah

Dokholyan

2022

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against cancer because of their high potency, specificity, versatility, rapid and large-scale development capability, low-cost manufacturing potential, and safety. Recent technological advances in mRNA vaccine design and delivery have accelerated mRNA cancer vaccines’ development and clinical application. In this review, we present various cancer vaccine platforms with a focus on nucleic acid vaccines. We discuss rational design and optimization strategies for mRNA cancer vaccine development. We highlight the platforms available for delivery of the mRNA vaccines with a focus on lipid nanoparticles (LNPs) based delivery systems. Finally, we discuss the limitations of mRNA cancer vaccines and future challenges.

show abstract

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

Cited by 23 publications

References 192 publications

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

mRNA vaccines for cancer immunotherapy

Contact Info

Product

Resources

About